Expanding the Molecular Disturbances of Lipoproteins in Cardiometabolic Diseases: Lessons from Lipidomics
The increasing global burden of cardiometabolic diseases highlights the urgent clinical need for better personalized prediction and intervention strategies. Early diagnosis and prevention could greatly reduce the enormous socio-economic burden posed by these states. Plasma lipids including total cho...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/4/721 |
| _version_ | 1797621515059986432 |
|---|---|
| author | Christina E. Kostara |
| author_facet | Christina E. Kostara |
| author_sort | Christina E. Kostara |
| collection | DOAJ |
| description | The increasing global burden of cardiometabolic diseases highlights the urgent clinical need for better personalized prediction and intervention strategies. Early diagnosis and prevention could greatly reduce the enormous socio-economic burden posed by these states. Plasma lipids including total cholesterol, triglycerides, HDL-C, and LDL-C have been at the center stage of the prediction and prevention strategies for cardiovascular disease; however, the bulk of cardiovascular disease events cannot be explained sufficiently by these lipid parameters. The shift from traditional serum lipid measurements that are poorly descriptive of the total serum lipidomic profile to comprehensive lipid profiling is an urgent need, since a wealth of metabolic information is currently underutilized in the clinical setting. The tremendous advances in the field of lipidomics in the last two decades has facilitated the research efforts to unravel the lipid dysregulation in cardiometabolic diseases, enabling the understanding of the underlying pathophysiological mechanisms and identification of predictive biomarkers beyond traditional lipids. This review presents an overview of the application of lipidomics in the study of serum lipoproteins in cardiometabolic diseases. Integrating the emerging multiomics with lipidomics holds great potential in moving toward this goal. |
| first_indexed | 2024-03-11T08:57:04Z |
| format | Article |
| id | doaj.art-89a4626882b14692816a3dd09e7c3e60 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-11T08:57:04Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-89a4626882b14692816a3dd09e7c3e602023-11-16T20:02:10ZengMDPI AGDiagnostics2075-44182023-02-0113472110.3390/diagnostics13040721Expanding the Molecular Disturbances of Lipoproteins in Cardiometabolic Diseases: Lessons from LipidomicsChristina E. Kostara0Laboratory of Clinical Chemistry, School of Health Sciences, Faculty of Medicine, University of Ioannina, 45110 Ioannina, GreeceThe increasing global burden of cardiometabolic diseases highlights the urgent clinical need for better personalized prediction and intervention strategies. Early diagnosis and prevention could greatly reduce the enormous socio-economic burden posed by these states. Plasma lipids including total cholesterol, triglycerides, HDL-C, and LDL-C have been at the center stage of the prediction and prevention strategies for cardiovascular disease; however, the bulk of cardiovascular disease events cannot be explained sufficiently by these lipid parameters. The shift from traditional serum lipid measurements that are poorly descriptive of the total serum lipidomic profile to comprehensive lipid profiling is an urgent need, since a wealth of metabolic information is currently underutilized in the clinical setting. The tremendous advances in the field of lipidomics in the last two decades has facilitated the research efforts to unravel the lipid dysregulation in cardiometabolic diseases, enabling the understanding of the underlying pathophysiological mechanisms and identification of predictive biomarkers beyond traditional lipids. This review presents an overview of the application of lipidomics in the study of serum lipoproteins in cardiometabolic diseases. Integrating the emerging multiomics with lipidomics holds great potential in moving toward this goal.https://www.mdpi.com/2075-4418/13/4/721lipidomicslipoproteinsmetabolismcardiometabolic diseasesobesitymetabolic syndrome |
| spellingShingle | Christina E. Kostara Expanding the Molecular Disturbances of Lipoproteins in Cardiometabolic Diseases: Lessons from Lipidomics Diagnostics lipidomics lipoproteins metabolism cardiometabolic diseases obesity metabolic syndrome |
| title | Expanding the Molecular Disturbances of Lipoproteins in Cardiometabolic Diseases: Lessons from Lipidomics |
| title_full | Expanding the Molecular Disturbances of Lipoproteins in Cardiometabolic Diseases: Lessons from Lipidomics |
| title_fullStr | Expanding the Molecular Disturbances of Lipoproteins in Cardiometabolic Diseases: Lessons from Lipidomics |
| title_full_unstemmed | Expanding the Molecular Disturbances of Lipoproteins in Cardiometabolic Diseases: Lessons from Lipidomics |
| title_short | Expanding the Molecular Disturbances of Lipoproteins in Cardiometabolic Diseases: Lessons from Lipidomics |
| title_sort | expanding the molecular disturbances of lipoproteins in cardiometabolic diseases lessons from lipidomics |
| topic | lipidomics lipoproteins metabolism cardiometabolic diseases obesity metabolic syndrome |
| url | https://www.mdpi.com/2075-4418/13/4/721 |
| work_keys_str_mv | AT christinaekostara expandingthemoleculardisturbancesoflipoproteinsincardiometabolicdiseaseslessonsfromlipidomics |